Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

We aimed to use physiologically based pharmacokinetic (PBPK) modeling and simulation to predict imatinib steady‐state plasma exposure in patients with chronic myeloid leukemia (CML) to investigate variability in outcomes. A validated imatinib PBPK model (Simcyp Simulator) was used to predict imatini...

Descripción completa

Detalles Bibliográficos
Autores principales: Adattini, Josephine A., Adiwidjaja, Jeffry, Gross, Annette S., McLachlan, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326685/
https://www.ncbi.nlm.nih.gov/pubmed/37417254
http://dx.doi.org/10.1002/prp2.1082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10326685/
https://www.ncbi.nlm.nih.gov/pubmed/37417254
http://dx.doi.org/10.1002/prp2.1082

Ejemplares similares